|
C9ORF80 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.99520433297585E-15 |
| Normal-vs-Stage2 |
1.85690000042982E-08 |
| Normal-vs-Stage3 |
1.11022302462516E-15 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
7.754400E-01 |
| Stage1-vs-Stage3 |
5.012200E-02 |
| Stage1-vs-Stage4 |
2.201000E-04 |
| Stage2-vs-Stage3 |
1.231950E-01 |
| Stage2-vs-Stage4 |
1.758800E-03 |
| Stage3-vs-Stage4 |
4.218000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.38490000001212E-06 |
| Normal-vs-Asian |
5.43350031634304E-10 |
| Caucasian-vs-AfricanAmerican |
4.471800E-01 |
| Caucasian-vs-Asian |
4.461400E-01 |
| AfricanAmerican-vs-Asian |
8.601200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.6251444634463E-12 |
| Male-vs-Female |
1.581720E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.10331752015236E-12 |
| Normal-vs-Age(41-60Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.09049999996724E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.623400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.394000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.161180E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.223410E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.202600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.881400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.463500E-03 |
| Classical-VS-Follicular |
7.688000E-01 |
| Classical-VS-Other |
1.536440E-01 |
| Classical-VS-Normal |
1.62647673107585E-12 |
| Tall-VS-Follicular |
1.704290E-02 |
| Tall-VS-Other |
8.648400E-01 |
| Tall-VS-Normal |
2.43438602609558E-12 |
| Follicular-VS-Other |
2.292200E-01 |
| Follicular-VS-Normal |
7.04509783844287E-11 |
| Other-VS-Normal |
2.09379999999149E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.99840144432528E-15 |
| Normal-vs-N1 |
6.68354260824344E-14 |
| N0-vs-N1 |
5.553600E-02 |
|
|
